No Data
CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Holdings' Shareholding in China Resources Boya Bio-pharmaceutical Group has reached 1%.
CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, public...
China Resources Boya Bio-pharmaceutical Group (300294.SZ): The controlling shareholder has increased their shareholding by 1%.
On December 18, GELONGHUI reported that China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that its controlling shareholder, CHINARES PHARMA Holdings Limited, increased its shareholding by a total of 5,042,400 shares through the Shenzhen Stock Exchange's trading system from November 8 to December 18, 2024, accounting for 1.0000% of the company's total share capital. CHINARES PHARMA plans to increase its shareholding of the company within six months starting from November 8, 2024, in a manner permitted by securities laws, with the total number of shares acquired (including this increase) not less than 1% of the total share capital (i.e., 5.0424 million shares), and not exceeding.
China Resources Boya Bio-pharmaceutical Group (300294.SZ): A subsidiary participates in the national Pharmaceutical centralized procurement and intends to be selected.
On December 16, Gelonghui reported that China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that its wholly-owned subsidiary Nanjing Xinjiekou Department Store participated in the bidding work organized by the National Organization of Pharmaceutical Procurement Office for the tenth batch of national centralized pharmaceutical procurement. Nanjing Xinjiekou Department Store's product, Carboprost Tromethamine Injection, is intended to win the bid for this centralized procurement. This product, Carboprost Tromethamine Injection, is expected to receive the "Drug Registration Certificate" approved and issued by the National Medical Products Administration in August 2024 and is a new product for Nanjing Xinjiekou Department Store, which has not generated any sales revenue in 2023.
China Resources Boya Bio-Pharmaceutical Group (300294.SZ): The company's products are not related to stem cells.
On December 2, Gelonghui reported that china resources boya bio-pharmaceutical group (300294.SZ) stated on the investor interaction platform that the company is mainly engaged in the research and development, production, and sales of blood products. Blood products refer to plasma protein products extracted from healthy human plasma through separation and purification methods. The company's products are not related to stem cells.
China Resources Boya Bio-Pharmaceutical Group (300294.SZ): 78.3086 million restricted shares will be unlocked on November 25th.
On November 19, Gelonghui announced that china resources boya bio-pharmaceutical group (300294.SZ) published a notice regarding the lifting of restrictions on the issuance of stocks to specific entities. The number of shares applying for unrestricted trading is 78,308,575 shares issued by china resources boya bio-pharmaceutical group limited (hereinafter referred to as the company) to specific entity chinares pharma holdings limited. This number of unrestricted shares accounts for 15.5298% of the company's total stock capital; after lifting the restrictions, the actual number of shares available for trading will be 78.308575 million shares, accounting for 15% of the company's total stock capital.
There May Be Reason For Hope In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Disappointing Earnings
Some Confidence Is Lacking In China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) As Shares Slide 26%
